The cost-effectiveness of needle and syringe provision in preventing transmission of Hepatitis C virus in people who inject drugs
PHE ePoster Library. Ward Z. 09/13/17; 186566; 11
Dr. Zoe Ward
Dr. Zoe Ward
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Rate & Comment (0)
Abstract Aim: Over 80% of Hepatitis C virus (HCV) infections in the UK are acquired through injecting drug use. This study investigated the cost-effectiveness of current levels of high coverage needle and syringe provision (HCNSP defined as a clean needle for every injection) compared to a counterfactual scenario of no provision of needle and syringe programmes (NSP) for 10 years in 3 UK settings with differing chronic prevalence: Bristol (45%), Walsall (24%) and Dundee (38%).Methods: A HCV transmission model was parameterised with UK estimates for the effect of HCNSP on HCV acquisition risk and city specific data and estimated the number of incident infections and disease related deaths. for each scenario. Primary cost data for city specific NSP was used to perform a cost-effectiveness analysis with a 50-year time-horizon and £20000 per quality adjusted life year (QALY) threshold for the incremental cost-effectiveness ratio (ICER).Results: Removing NSP for 10 years increased the number of incident infections in line with the prevalence of HCV in each city (Bristol 200, Walsall 93, Dundee 749). The mean ICER was cost saving in Dundee and Bristol, and £600 per QALY in Walsall. These results were robust to univariate sensitivity analyses undertaken including time horizon, HCV treatment cost and discount rate. Discussion: Despite variations in coverage, NSP are preventing considerable HCV infections in the UK. NSP are cost effective at the £20000 per QALY threshold or cost saving. Removing NSP is likely to lead to drastically increased long term healthcare costs. External funding details NIHR funded project
Abstract Aim: Over 80% of Hepatitis C virus (HCV) infections in the UK are acquired through injecting drug use. This study investigated the cost-effectiveness of current levels of high coverage needle and syringe provision (HCNSP defined as a clean needle for every injection) compared to a counterfactual scenario of no provision of needle and syringe programmes (NSP) for 10 years in 3 UK settings with differing chronic prevalence: Bristol (45%), Walsall (24%) and Dundee (38%).Methods: A HCV transmission model was parameterised with UK estimates for the effect of HCNSP on HCV acquisition risk and city specific data and estimated the number of incident infections and disease related deaths. for each scenario. Primary cost data for city specific NSP was used to perform a cost-effectiveness analysis with a 50-year time-horizon and £20000 per quality adjusted life year (QALY) threshold for the incremental cost-effectiveness ratio (ICER).Results: Removing NSP for 10 years increased the number of incident infections in line with the prevalence of HCV in each city (Bristol 200, Walsall 93, Dundee 749). The mean ICER was cost saving in Dundee and Bristol, and £600 per QALY in Walsall. These results were robust to univariate sensitivity analyses undertaken including time horizon, HCV treatment cost and discount rate. Discussion: Despite variations in coverage, NSP are preventing considerable HCV infections in the UK. NSP are cost effective at the £20000 per QALY threshold or cost saving. Removing NSP is likely to lead to drastically increased long term healthcare costs. External funding details NIHR funded project
    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings